Discovery & Development
IP Intellectual property
R&D/POC/Validation
Preclinical
Clinical Translational
Phase I/II
Phase III
Regulatory
Delivery
Commercial
Phase IV
IND application
New Drug Application(NDA)

Scientists

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Kumar V. Penmetsa, PhD

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Sudhir Manda MD, FACP

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Sudhir Manda MD, FACP

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Researches

Researchers

Clinical data manager

Doctors

Project manager

Regulatory agencies

Drug manufacturer

Research scientist

Scientists

Shailaja
Srinivas

Researches

Researchers

Project manager

Clinical data manager

Regulatory agencies

Drug manufacturer

Research scientist

Discovery & Development
IP Intellectual property
R&D/POC/Validation
Preclinical
Clinical Translational
Phase I/II
Phase III
Regulatory
Delivery
Commercial
Phase IV
IND application
New Drug Application(NDA)

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Kumar V. Penmetsa, PhD

Sudhir Manda MD, FACP

Sudhir Manda MD, FACP

Kumar V. Penmetsa, PhD

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Scientists

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Kumar V. Penmetsa, PhD

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Sudhir Manda MD, FACP

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Sudhir Manda MD, FACP

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Researches

Researchers

Clinical data manager

Doctors

Project manager

Regulatory agencies

Drug manufacturer

Research scientist

Scientists

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Kumar V. Penmetsa, PhD

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Sudhir Manda MD, FACP

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Sudhir Manda MD, FACP

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Researches

Researchers

Clinical data manager

Doctors

Project manager

Regulatory agencies

Drug manufacturer

Research scientist

Discovery & Development
IP Intellectual Property
R&D/POC/Validation
Preclinical
IND application
Clinical Translational
Phase I/II
Phase IIi
Regulatory
New Drug Application(NDA)
Delivery
Commercial
Phase IV

Scientists

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Sudhir Manda MD, FACP

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Researches

Researchers

Clinical data manager

Doctors

Project manager

Regulatory agencies

Drug manufacturer

Research scientist

Scientists

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Sudhir Manda MD, FACP

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Researches

Researchers

Clinical data manager

Doctors

Project manager

Regulatory agencies

Drug manufacturer

Research scientist

Scientists

Doctors

Researches

Researchers

Project manager

Clinical data manager

Regulatory agencies

Drug manufacturer

Research scientist

Doctors

Scientists

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Shailaja Kasibhatla, PhD

Srinivas R. Kasibhatla, PhD

Kumar V. Penmetsa, PhD

Sudhir Manda MD, FACP

Researches

Clinical data manager

Project Manager

Regulatory agencies

Drug Manufacturer

Research Scientist

Linkedin

Copyright 2024 © All rights Reserved.

Copyright 2024 © All rights Reserved.

Shailaja Kasibhatla, PhD

Dr. Kasibhatla, is the Vice President of Boundless Bio. She has more than 20 years of experience in the pharmaceutical industry and has contributed to the advancement of more than 10 programs towards clinical proof of concept. She served as Senior Director of Translational Development at Bristol-Myers Squibb (BMS) where she led the cohesive scientific, and strategic integration of early translational development across multiple protein degrader programs and managed these programs from preclinical to clinical proof of concept.

Srinivas R. Kasibhatla, PhD

Dr. Srinivas R. Kasibhatla is currently the founder and CEO of Innovative Discovery Partners at San Diego, started by him in 2018, where he is a Pharmaceutical consultant working in the areas of medicinal chemistry, drug discovery project management, and intellectual property. He has over 25 years of drug discovery experience in multinational pharmaceuticals and small biotech companies across multiple therapeutic areas that include cancer, diabetes, obesity, Neuroscience, immunology, cardiovascular and infectious diseases. He has contributed to the discovery of 11 clinical candidates – cancer (4), diabetes (2), immunology (1), Neuroscience (1) and cardiovascular (2). He was the lead inventor or co-inventor on several issued and published patents.

Kumar V. Penmetsa, PhD

Kumar Penmetsa has over 26 years of biotech and pharma industry experience. Kumar worked at Bristol-Myers Squibb Company for 15 years. During his time at BMS, Kumar managed R&D Operations functions in Oncology, Immunology, and Cardio-Metabolic diseases.  Kumar also has consulting experience in biopharma R&D Strategy and Corporate Development.  Kumar is currently a Senior Director, Global Development Consulting within the Clinical Research Group at Thermo Fisher Scientific.  He graduated with a Ph.D. from N. C. State University, USA.

Sudhir Manda MD, FACP

Dr. Manda is a Medical Oncologist& Hematologist at Arizona Oncology. Dr Manda is actively involved in both hematology and GI clinical trials through the US Oncology Network Research program. His areas of expertise are gastrointestinal cancers, which include colorectal, pancreatic, biliary, hepatocellular, gastric and esophageal cancers. He has a focused interest in the field of GI malignancies that includes detection and treatment of colorectal and other gastrointestinal neoplasms.